Abstract
Objectives Autologous blood transfusion (ABT) enhances athlete’s performance, is banned as doping by the World Anti-Doping Agency (WADA). Currently, there is no implemented detection method for ABT. Transfusion of one’s own, long-term cryopreserved red blood cells (cryo-RBC) immediately increases circulating RBC count, hemoglobin mass, blood volume and oxygen carrying capacity, resulting in enhanced physical performance. Functional viablity of cryo-RBC are maintained for decades, but storage lesions lead to removal of damaged RBC from circulation days after transfusion, with remaining circulating cryo-RBC displaying normal half-life.
Methods The cytosolic RBC peptidome from 22 human subjects (12 men and 10 women) was analyzed by UHPLC-MS/MS before and after ABT with cryo-RBC. As a control group and for investigation of confounders, 14 elite athletes and 5 recreational subjects were sampled multiple times, also at high altitude.
Results Here we report alteration in the cytosolic peptidome of circulating RBC weeks after ABT, discriminating doped from non-doped human subjects. A valid discriminating multivariate model (OPLS-DA) based on <200 peptides was accomplished (R2/Q2 = 0.88/0.59, P CV-ANOVA < 0.0001, ROC AUC = 0.97). Models did not show bias for sex, high altitude or elite endurance training and racing.
Conclusion Identified peptides with low intra- and inter-individual variation, and high multivariate model weight and probability scores, create a direct method for the detection of autologous blood doping.
Competing Interest Statement
CM, IG and NK are part owners of Pro Test Diagnostics AB
Funding Statement
This work was supported and funded by World Anti-Doping Agency (WADA) R07A1CM, 08C06CM and T13M04CM (http://wada-ama.org), Sweden’s Innovation Agency (VINNOVA) 2009-00462, 2013-05410, 2015-05299, 2018-01881 (http://vinnova.se), Centrum för Idrottsforskning (CIF) 2008 88/08 (http://centrumforidrottsforskning.se) and Umeå Biotech Incubator (http://ubi.se). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Board for Northern Sweden (DNr: Ö;1-2009, 08-196M, 2011-408-32M). All participants provided written informed consent, were screened by a hematologist physician before entering the study, and all transfusions performed according to state-approved clinical procedures at Swedish hospitals. Risks reviewed in Appendix 1. Some subjects performed maximal physical work, which may give discomfort, but activities were voluntary and could be stopped at any time. The study was conducted in accordance with the WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects 2013. Data is encrypted, stored on security protected servers. Only approved staff has access to data and code keys.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available in Supplementary files
https://www.dropbox.com/sh/vprl88p6binepmb/AACVJ-mV6jdvqvwDMGDvic30a?dl=0
